HDFC Pharma and Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • 0.8 %Nav, as on 30-01-2025

  • Previous Nav

  • Net Change on 30-01-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
BSE Health Care - TRI -7.85 -3.44 27.07 21.15 24.96 15.70
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 16.72 19.72 25.58 0.91 8,914.89
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - Cumulative Option Jul 13, 2018 29.25 24.26 28.49 1.08 5,320.29
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 27.90 24.47 27.81 0.89 3,628.03
DSP Healthcare Fund - Direct Plan - Growth Nov 30, 2018 26.19 22.66 28.37 0.57 3,339.79
Mirae Asset Healthcare Fund Direct Growth Jul 02, 2018 23.17 19.38 27.27 0.49 2,863.52

Fund Holdings as on 31-December-2024

  • Sun Pharmaceutical Industries Ltd.

  • Cipla Ltd.

  • Divis Laboratories Ltd.

  • Lupin Ltd.

  • Aster DM Healthcare Limited

  • Ipca Laboratories Ltd.

  • Gland Pharma Ltd.

  • Krishna Institute Of Medical Sciences Limited

  • TREPS - Tri-party Repo

  • Glenmark Pharmaceuticals Ltd.

  • Dr Reddys Laboratories Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Wockhardt Ltd.

  • Eris Lifesciences Ltd

  • VIJAYA DIAGNOSTIC CENTRE LTD.

  • PIRAMAL PHARMA LTD

  • Metropolis Healthcare Ltd.

  • Aurobindo Pharma Ltd.

  • Ajanta Pharma Limited

  • Fortis Healthcare Limited

  • Max Healthcare Institute Limited

  • Zydus Lifesciences Limited

  • Laurus Labs Ltd.

  • AMI Organics Ltd

  • BAJAJ HEALTHCARE LIMITED - Prefential Issue

  • Pfizer Ltd.

  • Jubilant Pharmova Limited

  • Medi Assist Healthcare Services Limited

  • Sai Life Sciences Limited

  • Unichem Laboratories Ltd.

  • Alembic Pharmaceuticals Limited

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Business Support

View More

Fund Manager

  • Education:PGDM - IMT, B.E. (Civil), CFA (USA)
  • Experience:7
  • Basic Details:Over 7 years of experience in equity research and 2 years in financial advisory.
  • Funds Managed:
  • HDFC Pharma and Healthcare Fund

  • Cash

  • Equity

View More

About HDFC Pharma and Healthcare Fund

Scheme Analysis

HDFC Pharma and Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to HDFC Mutual Fund. It was launched on 04-Oct-2023 and currently has an AUM of ₹1,577.12 crore. HDFC Pharma and Healthcare Fund is benchmarked against BSE Health Care - TRI as primary index and NIFTY 50 - TRI as secondary index.

The NAV of HDFC Pharma and Healthcare Fund ended up ₹0.13(0.8%)yesterday to ₹16.045.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The HDFC Pharma and Healthcare Fund is managed by Nikhil Mathur .

Fund House Contact

HDFC House, 2nd floor, H.T. Parekh Marg, 165-166 Backbay Reclamation, Churchgate Mumbai - 400 020

+91 (22) 66316333
cliser@hdfcindia.com
+91 (22) 22821144